U.S. Markets close in 4 hrs 18 mins
  • S&P 500

    4,403.79
    +49.60 (+1.14%)
     
  • Dow 30

    34,349.03
    +429.19 (+1.27%)
     
  • Nasdaq

    14,899.92
    +153.52 (+1.04%)
     
  • Russell 2000

    2,221.06
    +34.87 (+1.60%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,778.00
    -0.20 (-0.01%)
     
  • Silver

    22.80
    +0.23 (+1.01%)
     
  • EUR/USD

    1.1741
    +0.0011 (+0.0939%)
     
  • 10-Yr Bond

    1.3180
    -0.0060 (-0.45%)
     
  • Vix

    21.47
    -2.89 (-11.86%)
     
  • GBP/USD

    1.3659
    -0.0005 (-0.0355%)
     
  • USD/JPY

    109.6050
    +0.3850 (+0.3525%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,073.98
    +33.50 (+3.22%)
     
  • FTSE 100

    7,080.48
    +99.50 (+1.43%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Fundamental Research Corp Updates Investment Analysis Coverage on THC Biomed

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

THC.CSE
THCBF
- OTC
TFHD.F

VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ - THC BioMed Intl Ltd. ("THC BioMed" or the "Company") discloses that Fundamental Research Corp. has updated its independent investment analysis coverage on THC BioMed with a note and change of valuation.

THC BioMed Intl Ltd. (CNW Group/THC BioMed)
THC BioMed Intl Ltd. (CNW Group/THC BioMed)

Fundamental Research Corp. is an issuer-paid independent research house. THC BioMed notes this development for information only and does not endorse the contents of Fundamental Research Corp.'s report.

About THC

THC BioMed is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services related in the medical cannabis industry. Management believes THC BioMed is well-positioned to be in the forefront of this rapidly growing industry.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this release are made as of the date of this press release and include that THC BioMed will be on the forefront of this rapidly growing industry. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/fundamental-research-corp-updates-investment-analysis-coverage-on-thc-biomed-301229761.html

SOURCE THC BioMed